Pro-Proliferative Function of Mitochondrial Sirtuin Deacetylase SIRT3 in Human Melanoma

Journal of Investigative Dermatology

Volumn 136, Issue 4, 2016, Pages 809-818

  George, Jasmine ^a   Nihal, Minakshi ^a   Singh, Chandra K ^a   Zhong, Weixiong ^b   Liu, Xiaoqi ^c   Ahmad, Nihal ^a,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c PURDUE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E1; CYCLINE; MESSENGER RNA; SHORT HAIRPIN RNA; SIRTUIN 3; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; SIRT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; HETEROCHROMATIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMORTALIZED CELL LINE; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PIGMENTED NEVUS; PRIORITY JOURNAL; PROTEIN FUNCTION; SENESCENCE; TISSUE MICROARRAY; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CELL AGING; CELL MOTION; CYTOLOGY; GENE EXPRESSION REGULATION; HEK293 CELL LINE; METABOLISM; NEVUS; NUDE MOUSE; PHENOTYPE; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; BETA-GALACTOSIDASE; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEVUS; PHENOTYPE; SIRTUIN 3; SKIN NEOPLASMS;

EID: 84978110953     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2015.12.026     Document Type: Article

References (41)

1. Alcorta, D.A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., Barrett, J.C., Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93 (1996), 13742–13747.
2. Alhazzazi, T.Y., Kamarajan, P., Joo, N., Huang, J.Y., Verdin, E., D'Silva, N.J., et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 117 (2011), 1670–1678.
3. Alhazzazi, T.Y., Kamarajan, P., Verdin, E., Kapila, Y.L., Sirtuin-3 (SIRT3) and the hallmarks of cancer. Genes Cancer 4 (2013), 164–171.
4. Ashraf, N., Zino, S., Macintyre, A., Kingsmore, D., Payne, A.P., George, W.D., et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 95 (2006), 1056–1061.
5. Ben-Porath, I., Weinberg, R.A., When cells get stressed: an integrative view of cellular senescence. J Clin Invest 113 (2004), 8–13.
6. Bosch-Presegue, L., Vaquero, A., The dual role of sirtuins in cancer. Genes Cancer 2 (2011), 648–662.
7. Chang, B.D., Broude, E.V., Dokmanovic, M., Zhu, H., Ruth, A., Xuan, Y., et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59 (1999), 3761–3767.
8. Chen, Y., Fu, L.L., Wen, X., Wang, X.Y., Liu, J., Cheng, Y., et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis, 5, 2014, e1047.
9. Chen, Y., Sprung, R., Tang, Y., Ball, H., Sangras, B., Kim, S.C., et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 6 (2007), 812–819.
10. Desouki, M.M., Doubinskaia, I., Gius, D., Abdulkadir, S.A., Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Hum Pathol 45 (2014), 1071–1077.
11. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92 (1995), 9363–9367.
12. Dobashi, Y., Shoji, M., Jiang, S.X., Kobayashi, M., Kawakubo, Y., Kameya, T., Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 153 (1998), 963–972.
13. Fang, L., Igarashi, M., Leung, J., Sugrue, M.M., Lee, S.W., Aaronson, S.A., p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18 (1999), 2789–2797.
14. Finley, L.W., Haigis, M.C., Metabolic regulation by SIRT3: implications for tumorigenesis. Trends Mol Med 18 (2012), 516–523.
15. Fotedar, R., Fitzgerald, P., Rousselle, T., Cannella, D., Doree, M., Messier, H., et al. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 12 (1996), 2155–2164.
16. Giralt, A., Villarroya, F., SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging. Biochem J 444 (2012), 1–10.
17. Guan, K.L., Xiong, Y., Regulation of intermediary metabolism by protein acetylation. Trends Biochem Sci 36 (2011), 108–116.
18. Huang, K.H., Hsu, C.C., Fang, W.L., Chi, C.W., Sung, M.T., Kao, H.L., et al. SIRT3 expression as a biomarker for better prognosis in gastric cancer. World J Surg 38 (2014), 910–917.
19. Jacobs, J.J., de Lange, T., Significant role for p16INK4a in p53-independent telomere-directed senescence. Curr Biol 14 (2004), 2302–2308.
20. Jeong, S.M., Lee, J., Finley, L.W., Schmidt, P.J., Fleming, M.D., Haigis, M.C., SIRT3 regulates cellular iron metabolism and cancer growth by repressing iron regulatory protein 1. Oncogene 34 (2015), 2115–2124.
21. Kato, S., Han, S.Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100 (2003), 8424–8429.
22. Li, H., Feng, Z., Wu, W., Li, J., Zhang, J., Xia, T., SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2. Int J Oncol 43 (2013), 1420–1430.
23. Liu, C., Huang, Z., Jiang, H., Shi, F., The sirtuin 3 expression profile is associated with pathological and clinical outcomes in colon cancer patients. Biomed Res Int, 2014, 2014, 871263.
24. Narita, M., Nunez, S., Heard, E., Narita, M., Lin, A.W., Hearn, S.A., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113 (2003), 703–716.
25. North, B.J., Verdin, E., Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol, 5, 2004, 224.
26. Phalke, S., Mzoughi, S., Bezzi, M., Jennifer, N., Mok, W.C., Low, D.H., et al. p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6. Nucleic Acids Res 40 (2012), 9534–9542.
27. +-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 21 (2007), 920–928.
28. Schmit, T.L., Nihal, M., Ndiaye, M., Setaluri, V., Spiegelman, V.S., Ahmad, N., Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Res 72 (2012), 3864–3872.
29. Sebastian, C., Satterstrom, F.K., Haigis, M.C., Mostoslavsky, R., From sirtuin biology to human diseases: an update. J Biol Chem 287 (2012), 42444–42452.
30. Sherr, C.J., Roberts, J.M., CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 (1999), 1501–1512.
31. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
32. Thao, S., Escalante-Semerena, J.C., Control of protein function by reversible Nvarepsilon-lysine acetylation in bacteria. Curr Opin Microbiol 14 (2011), 200–204.
33. Wang, J.X., Yi, Y., Li, Y.W., Cai, X.Y., He, H.W., Ni, X.C., et al. Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. BMC Cancer, 14, 2014, 297.
34. Wang, Q., Zhang, Y., Yang, C., Xiong, H., Lin, Y., Yao, J., et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 327 (2010), 1004–1007.
35. Wilking, M.J., Singh, C., Nihal, M., Zhong, W., Ahmad, N., SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys 563 (2014), 94–100.
36. Yan, S.M., Han, X., Han, P.J., Chen, H.M., Huang, L.Y., Li Y.SIRT3 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Med Oncol, 31, 2014, 103.
37. Yang, B., Fu, X., Shao, L., Ding, Y., Zeng, D., Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human gastric cancer. Biochem Biophys Res Commun 443 (2014), 156–160.
38. Yang, M., Yang, C., Pei, Y., Effects of downregulation of SIRT3 expression on proliferation and apoptosis in esophageal squamous cell carcinoma EC9706 cells and its molecular mechanisms. Biomed Mater Eng 24 (2014), 3883–3890.
39. Zeng, Y.X., el-Deiry, W.S., Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12 (1996), 1557–1564.
40. Zhang, C.Z., Liu, L., Cai, M., Pan, Y., Fu, J., Cao, Y., et al. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One, 7, 2012, e51703.
41. Zhao, Y., Yang, H., Wang, X., Zhang, R., Wang, C., Guo, Z., Sirtuin-3 (SIRT3) expression is associated with overall survival in esophageal cancer. Ann Diagn Pathol 17 (2013), 483–485.